Evaluation of Viloxazine and Its Metabolite 5-Hydroxy-viloxazine Glucuronide Into Breast Milk in Healthy Lactating Women
PHASE4CompletedINTERVENTIONAL
Enrollment
15
Participants
Timeline
Start Date
May 23, 2023
Primary Completion Date
September 20, 2023
Study Completion Date
September 20, 2023
Conditions
Healthy Lactating Women
Interventions
DRUG
SPN-812 (600mg, QD)
Viloxazine ER
Trial Locations (1)
89113
PPD Phase I Clinic, Las Vegas
All Listed Sponsors
lead
Supernus Pharmaceuticals, Inc.
INDUSTRY
NCT06259331 - Evaluation of Viloxazine and Its Metabolite 5-Hydroxy-viloxazine Glucuronide Into Breast Milk in Healthy Lactating Women | Biotech Hunter | Biotech Hunter